CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 160 filers reported holding CRISPR THERAPEUTICS AG in Q4 2018. The put-call ratio across all filers is 1.91 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $20,190,000 | -32.3% | 266,430 | 0.0% | 0.57% | -23.3% |
Q3 2021 | $29,822,000 | -30.9% | 266,430 | 0.0% | 0.74% | -32.2% |
Q2 2021 | $43,132,000 | +32.9% | 266,430 | 0.0% | 1.10% | +13.2% |
Q1 2021 | $32,464,000 | -20.4% | 266,430 | 0.0% | 0.97% | -20.0% |
Q4 2020 | $40,793,000 | +83.1% | 266,430 | 0.0% | 1.21% | +21.1% |
Q3 2020 | $22,284,000 | +13.8% | 266,430 | 0.0% | 1.00% | -13.9% |
Q2 2020 | $19,580,000 | +73.3% | 266,430 | 0.0% | 1.16% | -3.3% |
Q1 2020 | $11,299,000 | +15.8% | 266,430 | +21.1% | 1.20% | +1.1% |
Q3 2018 | $9,757,000 | -24.5% | 220,000 | 0.0% | 1.19% | -34.4% |
Q2 2018 | $12,927,000 | +109.5% | 220,000 | +63.0% | 1.81% | +66.6% |
Q1 2018 | $6,171,000 | – | 135,000 | – | 1.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |